GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004312220 | Esophagus | HGIN | regulation of I-kappaB kinase/NF-kappaB signaling | 63/2587 | 249/18723 | 8.91e-07 | 3.61e-05 | 63 |
GO:000724918 | Esophagus | HGIN | I-kappaB kinase/NF-kappaB signaling | 67/2587 | 281/18723 | 3.84e-06 | 1.29e-04 | 67 |
GO:004312317 | Esophagus | HGIN | positive regulation of I-kappaB kinase/NF-kappaB signaling | 49/2587 | 186/18723 | 4.22e-06 | 1.40e-04 | 49 |
GO:00435435 | Esophagus | HGIN | protein acylation | 51/2587 | 243/18723 | 1.33e-03 | 1.57e-02 | 51 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
GO:0048011 | Esophagus | ESCC | neurotrophin TRK receptor signaling pathway | 17/8552 | 24/18723 | 1.13e-02 | 3.81e-02 | 17 |
GO:00435437 | Thyroid | PTC | protein acylation | 134/5968 | 243/18723 | 4.22e-14 | 2.58e-12 | 134 |
GO:004312226 | Thyroid | PTC | regulation of I-kappaB kinase/NF-kappaB signaling | 118/5968 | 249/18723 | 2.04e-07 | 3.63e-06 | 118 |
GO:000724926 | Thyroid | PTC | I-kappaB kinase/NF-kappaB signaling | 130/5968 | 281/18723 | 2.78e-07 | 4.80e-06 | 130 |
GO:006156419 | Thyroid | PTC | axon development | 199/5968 | 467/18723 | 5.27e-07 | 8.53e-06 | 199 |
GO:004312320 | Thyroid | PTC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 91/5968 | 186/18723 | 8.76e-07 | 1.33e-05 | 91 |
GO:000740918 | Thyroid | PTC | axonogenesis | 178/5968 | 418/18723 | 2.17e-06 | 2.91e-05 | 178 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZDHHC17 | SNV | Missense_Mutation | | c.1304N>A | p.Leu435His | p.L435H | Q8IUH5 | protein_coding | tolerated(0.54) | probably_damaging(0.935) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.1590G>T | p.Trp530Cys | p.W530C | Q8IUH5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.1758N>G | p.Phe586Leu | p.F586L | Q8IUH5 | protein_coding | deleterious(0) | possibly_damaging(0.783) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.1786G>C | p.Asp596His | p.D596H | Q8IUH5 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.1390G>C | p.Asp464His | p.D464H | Q8IUH5 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.145N>G | p.Arg49Gly | p.R49G | Q8IUH5 | protein_coding | tolerated(0.05) | benign(0.023) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.1156T>G | p.Phe386Val | p.F386V | Q8IUH5 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZDHHC17 | SNV | Missense_Mutation | novel | c.1748N>G | p.Glu583Gly | p.E583G | Q8IUH5 | protein_coding | tolerated(0.08) | benign(0.25) | TCGA-ZJ-AAXB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.248T>C | p.Val83Ala | p.V83A | Q8IUH5 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZDHHC17 | SNV | Missense_Mutation | | c.1340N>T | p.Pro447Leu | p.P447L | Q8IUH5 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |